Navigation Links
InterMune Initiates Phase 3 ASCEND Study of Pirfenidone in IPF
Date:7/7/2011

BRISBANE, Calif., July 7, 2011 /PRNewswire/ -- InterMune (NASDAQ: ITMN) today announced that patient enrollment has begun in ASCEND, a new Phase 3 study of pirfenidone for patients who suffer from idiopathic pulmonary fibrosis (IPF).  ASCEND is a multinational, randomized, double-blind, placebo controlled Phase 3 trial designed to evaluate the safety and efficacy of Esbriet® (pirfenidone) in IPF patients with mild to moderate impairment in lung function.  The primary endpoint is lung function, as measured by change in forced vital capacity (FVC) from baseline to Week 52.  The trial will enroll a total of approximately 500 patients who will be randomly assigned 1 to 1 to receive oral pirfenidone (2403 mg/day) or placebo.  Patients will be enrolled at centers in the United States, Mexico, South America, Australia and New Zealand.  

Steve Porter, M.D., Ph.D., Chief Medical Officer of InterMune, said, "We are very pleased to report enrollment of the first patient in ASCEND.  This study represents our continued commitment to making Esbriet available for the more than 100,000 IPF patients in the United States who are afflicted with IPF but currently have no FDA-approved therapies available to them."  

ASCEND Phase 3 Trial

InterMune's new Phase 3 study of pirfenidone is named ASCEND (Assessment of Pirfenidone to Confirm Efficacy and Safety in IPF).  ASCEND will add to pirfenidone's body of clinical evidence and support a future submission for FDA approval.

InterMune expects the trial to be fully enrolled by the first half of 2012, and that results from the study will be available in mid-2013.  InterMune anticipates a New Drug Application (NDA) resubmission for pirfenidone in the second half of 2013 and an FDA action in the first half of 2014.  

Relative to InterMune's previous studies o
'/>"/>

SOURCE InterMune, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. InterMune to Present at Canaccord Adams Conference
2. InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche
3. InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting
4. InterMune Reports Japanese Regulatory Approval of Pirfenidone in IPF
5. InterMune to Release Third Quarter 2008 Financial Results on November 6
6. InterMune Reports Third Quarter 2008 Financial Results and Business Highlights
7. InterMune to Present at Deutsche Bank Biotech Boston Confab
8. InterMune to Present at J.P. Morgan Healthcare Conference
9. InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF
10. InterMune Announces Pricing of Public Offering of 3,500,000 Shares of Common Stock
11. InterMune Announces Issuance of U.S. Patent for ITMN-191
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... Research and Markets ( http://www.researchandmarkets.com/research/k6lcp2/mexico_biomedical ) has ... Market - Growth, Trends & Forecasts (2014-2020)" report ... Biomedical Sensors market is estimated at $0.20 billion by ... 2014-2020 The near future will bring biomedical ... each individual. These sensors can be set to trigger ...
(Date:8/31/2015)... , Aug. 31, 2015  RXi Pharmaceuticals ... focused on discovering and developing innovative therapies primarily ... announced that the 30-day review period following the ... for ocular indications with the U.S. Food and ... is now active. Logo -  ...
(Date:8/31/2015)... 2015 Trimb Healthcare AB ("Trimb") today announced ... Group BV ("YouMedical"), a Dutch OTC company with operations ... of approximately EUR 16 million, with solid growth and ... ambition is to build a leading international OTC company, ... goal. YouMedical gives us a stronger North European OTC ...
(Date:8/30/2015)... England , August 31, 2015 ... Wartezeit   einer Frau   für chirurgische   Behandlung ... Alter von 7-90   werden für eine   ... soll 1200 Frauen behandeln und die Anzahl ausgebildeter Chirurgen ... Astellas gab heute bekannt, dass  Action on ...
Breaking Biology Technology:Mexico Biomedical Sensors Market Report 2015-2020 2RXi Pharmaceuticals Announces Advancements in its Ophthalmology Clinical Program with RXI-109 2RXi Pharmaceuticals Announces Advancements in its Ophthalmology Clinical Program with RXI-109 3RXi Pharmaceuticals Announces Advancements in its Ophthalmology Clinical Program with RXI-109 4Über 550 Frauen, deren Leben durch "Action on Fistula" transformiert wurde 2Über 550 Frauen, deren Leben durch "Action on Fistula" transformiert wurde 3Über 550 Frauen, deren Leben durch "Action on Fistula" transformiert wurde 4Über 550 Frauen, deren Leben durch "Action on Fistula" transformiert wurde 5
... major obstacle in producing transistors from networks of carbon ... print circuits on plastic sheets for applications including flexible ... aircraft to monitor crack formation. , The so-called "nanonet" ... overlapping in a fishnet-like structure - has been plagued ...
... or the Company), (Nasdaq: ERES ), a ... and other services to the,pharmaceutical, biotechnology, medical device ... Keith D. Schneck as Executive Vice,President and Chief ... Schneck joins eRT with over 30 years of ...
... 8%, - Non-GAAP Operating Earnings Down 6%, GAAP Operating ... Non-GAAP Diluted EPS Down 2%, GAAP Diluted EPS Down 19%, ... today reported third fiscal quarter 2008 revenues of,$244.4 million, representing ... third quarter of fiscal year 2007. Sales grew for both,industrial ...
Cached Biology Technology:'Nanonet' circuits closer to making flexible electronics reality 2'Nanonet' circuits closer to making flexible electronics reality 3'Nanonet' circuits closer to making flexible electronics reality 4eResearchTechnology Names New Chief Financial Officer 2eResearchTechnology Names New Chief Financial Officer 3Varian, Inc. Reports Third Quarter 2008 Results 2Varian, Inc. Reports Third Quarter 2008 Results 3Varian, Inc. Reports Third Quarter 2008 Results 4Varian, Inc. Reports Third Quarter 2008 Results 5Varian, Inc. Reports Third Quarter 2008 Results 6Varian, Inc. Reports Third Quarter 2008 Results 7Varian, Inc. Reports Third Quarter 2008 Results 8Varian, Inc. Reports Third Quarter 2008 Results 9Varian, Inc. Reports Third Quarter 2008 Results 10Varian, Inc. Reports Third Quarter 2008 Results 11Varian, Inc. Reports Third Quarter 2008 Results 12Varian, Inc. Reports Third Quarter 2008 Results 13Varian, Inc. Reports Third Quarter 2008 Results 14Varian, Inc. Reports Third Quarter 2008 Results 15Varian, Inc. Reports Third Quarter 2008 Results 16Varian, Inc. Reports Third Quarter 2008 Results 17Varian, Inc. Reports Third Quarter 2008 Results 18Varian, Inc. Reports Third Quarter 2008 Results 19Varian, Inc. Reports Third Quarter 2008 Results 20Varian, Inc. Reports Third Quarter 2008 Results 21Varian, Inc. Reports Third Quarter 2008 Results 22Varian, Inc. Reports Third Quarter 2008 Results 23Varian, Inc. Reports Third Quarter 2008 Results 24Varian, Inc. Reports Third Quarter 2008 Results 25
(Date:8/12/2015)... Aug. 12, 2015  Synaptics Inc. (NASDAQ: ... solutions, today announced that four of its fingerprint ... have officially been named FIDO Certified™ by the ... the certification, Synaptics, Natural ID™ fingerprint solutions are ... Framework (UAF) standard and are interoperable among other ...
(Date:8/6/2015)... TELTOW, Germany , August 6, 2015 ... SensoMotoric Instruments (SMI) shows the world,s first ... based on Epson,s Moverio BT-200 see-through head mounted ... this new solution, unprecedented quality and efficiency is brought ... context-sensitive displays. For the first time, professionals and researchers ...
(Date:8/4/2015)... , Aug. 04, 2015 ... http://www.researchandmarkets.com/research/nvh7k2/digital_forensics ) has announced the addition of ... (Hardware, Software, and Service), Sub-Segment (Computer Forensics, ... Forensics), Tool Types, Service, Vertical and Region ... to their offering. By Component ...
Breaking Biology News(10 mins):Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 3SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 2SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 3Digital Forensics Market - The Market Represents a Compound Annual Growth Rate (CAGR) of 11.3% From 2015 to 2020 2
... University professor is helping students improve their confidence ... learning. Candice Shoemaker, professor of horticulture, has ... and self-efficacy. Self-efficacy involves student confidence in understanding ... learning and achievement. Shoemaker,s published research appeared in ...
... University of Guam ecologist Thomas Marler recently mobilized efforts ... eruption of Mount Pinatubo, Philippines. "My interest was sparked ... was so powerful it changed global climate, yet after ... ecosystem had not been studied," said Marler. ...
... of all women scientists and one-quarter of male scientists at ... them from having as many children as they had wanted, ... Methodist University (SMU). The study, "Scientists Want More ... and Anne Lincoln of SMU and appears in the current ...
Cached Biology News:Finding their way: Study shows connection between academic direction and student learning 2Finding their way: Study shows connection between academic direction and student learning 3Guam researcher studies Mount Pinatubo ecosystem recovery 2Many top US scientists wish they had more children 2Many top US scientists wish they had more children 3
... data collection and automation that is controlled from ... Excel , Pre-configured library of interfaces for ... can be added and configured by the user ... into one spreadsheet , Allows for ...
...
Peptide-affinity Purified Polyclonal Antibody to MAML1 / Mastermind Peptide with sequence VLPTCPMAEFALPR, from N Terminus of the protein sequence according to NP_055572....
One unit is equal to 10Kb (insert DNA + vector). The final cost will increase or decrease according to the final assembled genome size. The price does not include genome annotation....
Biology Products: